Risperidone Implant For Schizophrenia Treatment Achieves Phase 2/3 Endpoint

Braeburn Parmaceuticals announced that a 6-month study of the risperidone implant treatment for schizophrenia has met its primary endpoint. This study tested the safety, tolerability, and pharmacokinetics of transferring consumers taking oral risperidone to the new BB0817 implant. Efficacy and safety of the implants were also assessed.

The study showed that the average plasma concentrations of risperidone of the BB0817 implant were comparable to the oral drug option throughout the 6-month study. 100% of those tested remained stable with no meaningful change to their condition. Adverse affects of the implant were similar to those in the oral dosage . . .